Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 10:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Metronidazole Gel Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Split-Face Tolerability Comparison Between MetroGel® 1% Versus Finacea® 15% in Subjects With Healthy Skin

NCT01139008
View directory record Official record
Conditions
Skin Manifestations
Interventions
metronidazole 1% gel, azelaic acid 15% gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Carrollton, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2022 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Phase 1 Interventional

A Therapeutic Equivalence Study of Two Metronidazole 1%Topical Gel Treatments for Patients With Rosacea

NCT01513863
View directory record Official record
Conditions
Rosacea
Interventions
Metronidazole Topical Gel 1%, Metronidazole Topical Gel 1% (Metrogel), Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
22
States / cities
Phoenix, Arizona • Long Beach, California • Newport Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2013 · Synced Sep 12, 2026, 10:35 AM EDT
Terminated Early Phase 1 Interventional

LUXSOL(TM) Topical Cream for the Treatment of Symptomatic Bacterial Vaginosis; A Proof of Concept Study

NCT02197182
View directory record Official record
Conditions
Bacterial Vaginosis (BV)
Interventions
LUXSOL copper containing cream, Metronidazole gel
Drug
Lead sponsor
CDA Research Group, Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Detroit, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Metronidazole Dermal Products

NCT03271983
View directory record Official record
Conditions
Bioequivalence
Interventions
Metronidazole gel 1, Metronidazole gel 2, Metronidazole cream
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Phase 4 Interventional

Assess the Ability of MetroGel 1% to Deliver Moisture to Facial Skin After a Single Application

NCT00436527
View directory record Official record
Conditions
Rosacea
Interventions
Metronidazole gel 1%
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Safety and Efficacy Study to Compare Two Rosacea Treatment Regimens

NCT00495313
View directory record Official record
Conditions
Rosacea
Interventions
doxycycline
Drug
Lead sponsor
CollaGenex Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
7
States / cities
Omaha, Nebraska • Las Vegas, Nevada • Arlington, Texas + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2008 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Phase 2 Interventional

Maternal Effects of Bacterial Vaginosis (BV) Treatment in Pregnancy

NCT00153517
View directory record Official record
Conditions
Vaginosis, Bacterial, Premature Birth, Birth Weight, Chorioamnionitis
Interventions
oral versus vaginal metronidazole
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
16 Years and older · Female only
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Sep 12, 2026, 10:35 AM EDT
Completed No phase listed Observational

Clinical Trial to Survey Results of Flourish Vaginal Care System for Recurrent Bacterial Vaginosis

NCT03734523
View directory record Official record
Conditions
Bacterial Vaginosis, Vaginal Flora Imbalance
Interventions
Flourish Vaginal Care System
Combination Product
Lead sponsor
Vaginal Biome Science
Other
Eligibility
18 Years to 52 Years · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Concord, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)

NCT02236156
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Metronidazole oral tablets 500mg, 1% SPL7013 Gel, Placebo gel
Drug
Lead sponsor
Starpharma Pty Ltd
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Phoenix, Arizona • San Diego, California • Metairie, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2018 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Phase 3 Interventional

A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea

NCT02393937
View directory record Official record
Conditions
Papulopustular Rosacea, Erythematotelangiectatic Rosacea
Interventions
Reference: Metronidazole Gel 1%, Test: Metronidazole Gel 1%, Placebo Gel
Drug
Lead sponsor
bioRASI, LLC
Industry
Eligibility
18 Years and older
Enrollment
963 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
27
States / cities
Los Angeles, California • San Diego, California • Boca Raton, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Phase 3 Interventional Results available

Multi-Center Study of New Medications to Treat Vaginal Infections

NCT02308033
View directory record Official record
Conditions
Vaginal Infection
Interventions
Metronidazole, Gel vehicle
Drug
Lead sponsor
Curatek Pharmaceuticals, LLC
Industry
Eligibility
12 Years and older · Female only
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Jonesboro, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2020 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal Products

NCT01813162
View directory record Official record
Conditions
HIV Prevention
Interventions
Tenofovir 1% gel, Vaginal product
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
San Francisco, California • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Phase 3 Interventional Results available

Multi-Center Study of New Medications to Treat Vaginal Infections

NCT02308046
View directory record Official record
Conditions
Vaginal Infection
Interventions
Terconazole, Placebo
Drug
Lead sponsor
Curatek Pharmaceuticals, LLC
Industry
Eligibility
12 Years and older · Female only
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
41
States / cities
Birmingham, Alabama • Chandler, Arizona • Scottsdale, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2020 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Phase 4 Interventional

Safety and Tolerability of Metronidazole Gel 1.3%

NCT02392026
View directory record Official record
Conditions
Vaginosis, Bacterial
Interventions
Metronidazole Gel
Drug
Lead sponsor
Insud Pharma
Industry
Eligibility
12 Years to 17 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
Long Beach, California • Paramount, California • Bardstown, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)

NCT02237950
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Metronidazole oral tablets 500mg, 1% SPL7013 Gel, Placebo gel
Drug
Lead sponsor
Starpharma Pty Ltd
Industry
Eligibility
16 Years to 45 Years · Female only
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
37
States / cities
Birmingham, Alabama • Montgomery, Alabama • Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2019 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Split-face Tolerability Comparison Between MetroGel® 1% vs Finacea® 15% in Subjects With Healthy Skin

NCT01139047
View directory record Official record
Conditions
Skin Manifestations
Interventions
metronidazole 1% gel, azelaic acid 15% gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 31, 2022 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Phase 2 Interventional

Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis

NCT01055106
View directory record Official record
Conditions
Vaginosis, Bacterial, Vaginal Infection
Interventions
GW05, Metronidazole
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
20
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2011 · Synced Sep 12, 2026, 10:35 AM EDT
Completed No phase listed Observational

An Evaluation of the Cosmetic Appearance of Metronidazole Gel (MetroGel®) 1%

NCT00668655
View directory record Official record
Conditions
Rosacea
Interventions
Metronidazole Gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
20 Years to 75 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Phase 2 Interventional

A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.

NCT00249782
View directory record Official record
Conditions
Rosacea
Interventions
Vehicle control, 2x/day, ACZONE (dapsone) Gel, 5%, 2x/day, ACZONE (dapsone) Gel, 5%, 1x/day, MetroGel® (metronidazole gel), 1.0% 1x/day, ACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM)
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
26
States / cities
Birmingham, Alabama • Tucson, Arizona • Fremont, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 29, 2011 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Not applicable Interventional Results available

Recurrent Bacterial Vaginosis and Vaginal Acidifying Gel Trial

NCT00545181
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Vaginal acidifying gel (RepHresh), Metronidazole control
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 11, 2010 · Synced Sep 12, 2026, 10:35 AM EDT
Completed No phase listed Observational

Preferences & Treatment Satisfaction Drivers in Rosacea Patients

NCT02602470
View directory record Official record
Conditions
Rosacea
Interventions
Azelaic Acid Gel including: Finacea (Azelaic Acid Gel 15%, BAY39-6251), Azelaic Acid Cream, Metronidazole gel, Metronidazole cream, Metronidazole Emulsion, Metronidazole Lotion, Brimonidine Tartrate Gel
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioavailability of Metronidazole Vaginal Gel in Healthy Subjects

NCT01020877
View directory record Official record
Conditions
Healthy
Interventions
Metronidazole
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2002
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2010 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Metronidazole SC Penetrance With Moisturizers

NCT06434519
View directory record Official record
Conditions
Rosacea, Erythematotelangiectatic
Interventions
Metronidazole cream, Cetaphil moisturizer, CeraVe moisturizer, Eucerin Healing Lotion moisturizer, Aveeno Calm and Restore Oat Gel moisturizer
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Phase 1Phase 2 Interventional

Bioequivalence of Metronidazole Gel, 0.75% in the Treatment of Bacterial Vaginosis

NCT01020396
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Metronidazole
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older · Female only
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
37
States / cities
Huntsville, Alabama • Fountain Valley, California • Washington D.C., District of Columbia + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 12, 2026, 10:35 AM EDT